GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aeolus Pharmaceuticals AOLS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Aeolus Pharmaceuticals — daily AOLS Delayed
Market value
$14,867
Last close × shares
Volume
100k
Shares, 30 Oct 2026

About Aeolus Pharmaceuticals

Its shares trade under the ticker AOLS. It has been listed since 2 February 1996. In the fiscal year to 30 September 2016, it reported revenue of $2.1m and a net loss of $3.6m. At that date it held total assets of $4.2m and shareholders' equity of $3.2m.

Aeolus Pharmaceuticals, Inc. engages in the development of a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease, and diseases of the central nervous system. The company is headquartered in Mission Viejo, California. The firm focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The firm's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.

Figures and description from our data supplier, not checked against the company's own report.

More about Aeolus Pharmaceuticals →

Latest on Aeolus Pharmaceuticals

Our reporting

We have not reported on Aeolus Pharmaceuticals yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Aeolus Pharmaceuticals's ticker?

Aeolus Pharmaceuticals trades as AOLS on its US listing, under ISIN US00765G1094.

What was Aeolus Pharmaceuticals's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.